QST-Pupillometry in Sickle Cell Disease Patients (QST)
Quantitative Sensory Testing and Pupillometry in Sickle Cell Disease Patients.
Sponsor: Julia Finkel
Listed as NCT02242058, this observational or N/A phase trial focuses on SCD With Severe Phenotype (HbSS, HbSβ0 Thalassemia, HbSOARab) and remains completed. Sponsored by Julia Finkel, it has been updated 14 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 9 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Mar 2020 — Nov 2020 [monthly]
Completed
-
Feb 2020 — Mar 2020 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jun 2018 — Feb 2020 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: EARLY_PHASE1 → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting EARLY_PHASE1
-
Feb 2017 — Aug 2017 [monthly]
Recruiting EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting Phase 0
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Julia Finkel
For direct contact, visit the study record on ClinicalTrials.gov .